Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
61st ASH Congress 2019: Menarini Ricerche presents the latest updates about the First In Human clinical trial of SEL24/MEN1703
Menarini Ricerche is progressing with the clinical development of SEL24/MEN1703, and will be presenting the design of the ongoing First In Human clinical trial DIAMOND-01 (NCT03008187) at the 61 st  ASH Congress
The delicate artistry of Fra Angelico is now a part of the Menarini Art Series
Fra Giovanni da Fiesole, known to the world as Fra Angelico, "Angelic friar”, truly believed that each brush stroke came from...
ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm
Promising results from the  preclinical study conducted by Menarini Ricerche on  MEN1611 , a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development  for the treatment ...
Menarini:  Elcin Barker Ergun Group CEO
The Board of Directors has appointed Mrs.  Elcin Barker Ergun   as CEO of Menarini Group.
Menarini’s evening with the stars of Fair Play
An evening dedicated to sport, courage and Fair Play, celebrating those who know how to win without cheating, relying only on their natural abilities, without ever giving in. 
Menarini Ricerche announces publication of pre-clinical data of the first-in-class antibody-drug conjugate MEN1309/OBT076,
Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205 Antibody-Drug Conjugate (ADC)  MEN1309 /OBT076. These findings have been published by...
Page 1 of 6First   Previous   [1]  2  3  4  5  6  Next   Last